Valuation : PolyPid Ltd.

Market Cap 103M 88.74M 83.2M 75.95M 143M 9.84B 144M 987M 385M 4.97B 387M 378M 16.47B P/E 2026 *
-5.7x
P/E 2027 * -4.13x
Enterprise Value 103M 88.74M 83.2M 75.95M 143M 9.84B 144M 987M 385M 4.97B 387M 378M 16.47B EV / Sales 2026 *
6.87x
EV / Sales 2027 * 11.9x
Free-Float
82.21%
Yield 2026 *
-
Yield 2027 * -
1 day-0.98%
1 week-0.59%
Current month+18.18%
1 month+35.20%
3 months+6.51%
6 months+19.29%
Current year+16.82%
1 week 4.96
Extreme 4.96
5.24
1 month 4.04
Extreme 4.04
5.24
Current year 3.65
Extreme 3.65
5.73
1 year 3.06
Extreme 3.06
5.73
3 years 2.3
Extreme 2.3
9.54
5 years 2.3
Extreme 2.3
289.2
10 years 2.3
Extreme 2.3
583.5
Manager TitleAgeSince
Chief Executive Officer 52 30/06/2022
Director of Finance/CFO 39 -
Chief Tech/Sci/R&D Officer 61 17/08/2025
Director TitleAgeSince
Director/Board Member 84 31/03/2008
Director/Board Member 52 07/08/2022
Director/Board Member 74 30/11/2018
Date Insider Type Main position Quantity % Market Cap.
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Director

9,132 0.0896%
15/07/26 Free

Chairman

9,132 0.0896%
Change 5-day change 1-year change 3-year change Capi.($)
-0.98%-0.59%+50.00%-39.75% 103M
-0.13%-6.44%+60.47%+112.05% 1,047B
+0.85%-0.81%+52.77%+63.15% 646B
-1.03%-3.58%+22.87%+73.29% 451B
-1.46%-4.50%+37.43%+38.41% 355B
-0.72%-2.89%+21.86%+36.79% 291B
-1.19%-2.21%+1.35%+12.29% 252B
-1.05%-1.57%+51.40%+68.55% 234B
+0.08%-1.78%-17.64%-54.29% 203B
-2.14%-0.30%+29.42%+89.10% 181B
Average -0.79%-2.47%+31.00%+39.96% 365.94B
Weighted average by Cap. -0.48%-3.46%+38.66%+65.51%

Financials

2026 *2027 *
Net sales 15M 12.93M 12.12M 11.06M 20.84M 1.43B 20.91M 144M 56.1M 724M 56.32M 55.09M 2.4B 8.68M 7.48M 7.01M 6.4M 12.05M 829M 12.09M 83.15M 32.44M 419M 32.57M 31.86M 1.39B
Net income -20.03M -17.26M -16.18M -14.77M -27.82M -1.91B -27.91M -192M -74.9M -966M -75.19M -73.55M -3.2B -31.55M -27.19M -25.49M -23.27M -43.83M -3.02B -43.97M -302M -118M -1.52B -118M -116M -5.05B
Net Debt - -
Logo PolyPid Ltd.
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.
Employees
72
Date Price Change Volume
28/08/26 US$5.070 -0.98% 63,723
27/08/26 US$5.120 +0.20% 78,068
26/08/26 US$5.110 +0.20% 149,344
25/08/26 US$5.100 +2.31% 139,606
24/08/26 US$4.985 -2.25% 124,422
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
5.070USD
Average target price
11.75USD
Spread / Average Target
+131.76%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PYPD Stock